Key result
Dipyridamole plus aspirin significantly inhibits spontaneous platelet aggregation versus placebo.
Why the study?
The effects of dipyridamole, aspirin, and their combination on whole blood platelet aggregation, PGI2 generation, and red cell deformability ex vivo were not fully characterized.
Does dipyridamole alone or in combination with aspirin inhibit platelet aggregation and affect PGI2 generation and red cell deformability in male volunteers?
RCT (n=16)
Double-blind
Randomised
Does dipyridamole alone or in combination with aspirin inhibit platelet aggregation and affect PGI2 generation and red cell deformability in male volunteers?
p-value: p=<0.0001
Dipyridamole and aspirin have additive inhibitory effects on spontaneous and collagen-induced platelet aggregation, but dipyridamole alone increases red cell deformability.
No takes yet. Share an insight, caveat, or question.
Supports combined dipyridamole-aspirin for platelet inhibition; extends RCT evidence on additive anti-aggregatory effects.
Saniabadi et al. (1991) reported an RCT. Dipyridamole and/or aspirin vs. Placebo was evaluated on Spontaneous platelet aggregation (p=<0.0001). The combination of dipyridamole and aspirin significantly inhibited spontaneous platelet aggregation compared with placebo (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: